These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 17286869)

  • 1. Prognostic implications of immunohistochemically detected YKL-40 expression in breast cancer.
    Kim SH; Das K; Noreen S; Coffman F; Hameed M
    World J Surg Oncol; 2007 Feb; 5():17. PubMed ID: 17286869
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High serum YKL-40 levels in patients with primary breast cancer is related to short recurrence free survival.
    Johansen JS; Christensen IJ; Riisbro R; Greenall M; Han C; Price PA; Smith K; Brünner N; Harris AL
    Breast Cancer Res Treat; 2003 Jul; 80(1):15-21. PubMed ID: 12889595
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum YKL-40 levels as a prognostic factor in patients with locally advanced breast cancer.
    Yamac D; Ozturk B; Coskun U; Tekin E; Sancak B; Yildiz R; Atalay C
    Adv Ther; 2008 Aug; 25(8):801-9. PubMed ID: 18670741
    [TBL] [Abstract][Full Text] [Related]  

  • 4. YKL-40 protein expression is not a prognostic marker in patients with primary breast cancer.
    Roslind A; Knoop AS; Jensen MB; Johansen JS; Nielsen DL; Price PA; Balslev E
    Breast Cancer Res Treat; 2008 Nov; 112(2):275-85. PubMed ID: 18157633
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High levels of serum HER-2/neu and YKL-40 independently reflect aggressiveness of metastatic breast cancer.
    Jensen BV; Johansen JS; Price PA
    Clin Cancer Res; 2003 Oct; 9(12):4423-34. PubMed ID: 14555515
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preoperative serum YKL-40 is a marker for detection and prognosis of endometrial cancer.
    Diefenbach CS; Shah Z; Iasonos A; Barakat RR; Levine DA; Aghajanian C; Sabbatini P; Hensley ML; Konner J; Tew W; Spriggs D; Fleisher M; Thaler H; Dupont J
    Gynecol Oncol; 2007 Feb; 104(2):435-42. PubMed ID: 17023034
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overexpression of YKL-40 is an independent prognostic marker in gastric cancer.
    Bi J; Lau SH; Lv ZL; Xie D; Li W; Lai YR; Zhong JM; Wu HQ; Su Q; He YL; Zhan WH; Wen JM; Guan XY
    Hum Pathol; 2009 Dec; 40(12):1790-7. PubMed ID: 19765801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased expression of the inflammatory protein YKL-40 in precancers of the breast.
    Qin W; Zhu W; Schlatter L; Miick R; Loy TS; Atasoy U; Hewett JE; Sauter ER
    Int J Cancer; 2007 Oct; 121(7):1536-42. PubMed ID: 17565739
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High serum levels of YKL-40 in patients with squamous cell carcinoma of the head and neck are associated with short survival.
    Roslind A; Johansen JS; Christensen IJ; Kiss K; Balslev E; Nielsen DL; Bentzen J; Price PA; Andersen E
    Int J Cancer; 2008 Feb; 122(4):857-63. PubMed ID: 17957792
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum YKL-40: a new potential marker of prognosis and location of metastases of patients with recurrent breast cancer.
    Johansen JS; Cintin C; Jørgensen M; Kamby C; Price PA
    Eur J Cancer; 1995; 31A(9):1437-42. PubMed ID: 7577068
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early detection and prognosis of ovarian cancer using serum YKL-40.
    Dupont J; Tanwar MK; Thaler HT; Fleisher M; Kauff N; Hensley ML; Sabbatini P; Anderson S; Aghajanian C; Holland EC; Spriggs DR
    J Clin Oncol; 2004 Aug; 22(16):3330-9. PubMed ID: 15310777
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum YKL-40 predicts relapse-free and overall survival in patients with American Joint Committee on Cancer stage I and II melanoma.
    Schmidt H; Johansen JS; Sjoegren P; Christensen IJ; Sorensen BS; Fode K; Larsen J; von der Maase H
    J Clin Oncol; 2006 Feb; 24(5):798-804. PubMed ID: 16391295
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elevated serum level of YKL-40 is an independent prognostic factor for poor survival in patients with metastatic melanoma.
    Schmidt H; Johansen JS; Gehl J; Geertsen PF; Fode K; von der Maase H
    Cancer; 2006 Mar; 106(5):1130-9. PubMed ID: 16456816
    [TBL] [Abstract][Full Text] [Related]  

  • 14. YKL-40 expression could be a poor prognostic marker in the breast cancer tissue.
    Kang EJ; Jung H; Woo OH; Park KH; Woo SU; Yang DS; Kim AR; Lee JB; Kim YH; Kim JS; Seo JH
    Tumour Biol; 2014 Jan; 35(1):277-86. PubMed ID: 23918300
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum YKL-40 and colorectal cancer.
    Cintin C; Johansen JS; Christensen IJ; Price PA; Sørensen S; Nielsen HJ
    Br J Cancer; 1999 Mar; 79(9-10):1494-9. PubMed ID: 10188896
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elevated pretreatment serum concentration of YKL-40-An independent prognostic biomarker for poor survival in patients with metastatic nonsmall cell lung cancer.
    Thöm I; Andritzky B; Schuch G; Burkholder I; Edler L; Johansen JS; Bokemeyer C; Schumacher U; Laack E
    Cancer; 2010 Sep; 116(17):4114-21. PubMed ID: 20564116
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum YKL-40, a new prognostic biomarker in cancer patients?
    Johansen JS; Jensen BV; Roslind A; Nielsen D; Price PA
    Cancer Epidemiol Biomarkers Prev; 2006 Feb; 15(2):194-202. PubMed ID: 16492905
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Breast cancer expression of YKL-40 correlates with tumour grade, poor differentiation, and other cancer markers.
    Shao R; Cao QJ; Arenas RB; Bigelow C; Bentley B; Yan W
    Br J Cancer; 2011 Oct; 105(8):1203-9. PubMed ID: 21934681
    [TBL] [Abstract][Full Text] [Related]  

  • 19. YKL-40 expression in benign and malignant lesions of the breast: a methodologic study.
    Roslind A; Johansen JS; Junker N; Nielsen DL; Dzaferi H; Price PA; Balslev E
    Appl Immunohistochem Mol Morphol; 2007 Dec; 15(4):371-81. PubMed ID: 18091378
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The importance of determining the prognostic marker YKL-40 in serum and tissues].
    Łata E; Gisterek I; Matkowski R; Szelachowska J; Kornafel J
    Pol Merkur Lekarski; 2010 Jun; 28(168):505-8. PubMed ID: 20642115
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.